Roivant's immune-modifying drug Lisraya demonstrated effectiveness in managing non-infectious uveitis, an inflammatory eye disease, in two Phase 3 trials involving 371 patients. The drug is expected to be approved in the first half of next year, potentially expanding its market beyond dermatomyositis, where it was previously approved. This development could unlock a significant new market for Roivant, which is estimated to have over 40,000 patients already receiving similar therapies.
Key points
Roivant's immune-modifying drug Lisraya showed promising results in treating non-infectio…: Roivant's immune-modifying drug Lisraya showed promising results in treating non-infectious uveitis, an inflammatory eye disease, in two Phase 3 trials involving 371 patients.
The drug is expected to be approved in the first half of next year, potentially expanding…: The drug is expected to be approved in the first half of next year, potentially expanding its market beyond dermatomyositis, where it was previously approved.
This development could unlock a significant new market for Roivant, which is estimated to…: This development could unlock a significant new market for Roivant, which is estimated to have over 40,000 patients already receiving similar therapies.
Sources checked by our analysis pipeline: 1
Roivant and its spinout Priovant said Wednesday that their immune-modifying pill Lisraya was more effective than placebo in treating the inflammatory eye disease non-infectious uveitis.
The results, from two Phase 3 trials spanning 371 patients, could unlock a new blockbuster market for Roivant. The company estimates that there are between 70,000 to 190,000 patients with the condition in the U.S., with over 40,000 of them already receiving Humira or a similar therapy.
Roivant plans to file for approval in the first half of next year. An approval would expand the drug’s use beyond the rare skin disease dermatomyositis, which it was OK’d for in August.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
The Emissions Gap Report 2026: The Point of Return warns that global warming will surpass 1.5°C above pre-industrial levels, necessitating urgent and drastic emissions cuts to return to the agreed threshold by the end of the century. To achieve this, countries must slash emissions by 18% by 2030, 45% by 2035, and 69% by 2040, compared with 2025 levels. The report emphasizes the importance of accelerating implementation of goals from the first Global Stocktake (GST) and calls for more opportunities to step up actio…
The United Nations warns El Niño could cause the Pacific Ocean to reach record temperatures, potentially leading to severe weather impacts and ecosystem changes. This underscores the ongoing concern over climate change's effects on the Earth's largest ocean.
Singapore faces challenges in identifying companies linked to fires during haze outbreaks, primarily due to a lack of up-to-date plantation maps and comprehensive company data. The Transboundary Haze Pollution Act, which allows fines of up to $100,000 per day and $2 million total, has proven difficult to enforce due to cross-border probes. Experts recommend stronger rules, including disclosure of plantation, supply chain, and ownership data, and earlier fire prevention measures.